Lupin Q1 net doubles

Revenues of the company stood at Rs 879.2 crore, a rise of 49 per cent from Rs 591.3 crore in the quarter last year. The company's global market revenues, too, recorded an 88 per cent increase at Rs 517.5 crore.

"The launch of ramipril in the US, after a successful litigation, bears testimony to the quality of our filings. Our investments in the European market and some of the emerging markets have begun to bear the fruit, which will stand us in good stead. We are confident of continuing this momentum in the coming quarters," said Kamal K Sharma, managing director, Lupin.

 

Lupin launched the generic version of ramipril, a hypertension drug, in the market during the quarter following a patent litigation win against the company that discovered the drug.